Niacinamide's Changes in the Skin Barrier

Niacinamide is the physiologically active form of vitamin B3 (niacin) that skin cells can use directly without conversion. It appears in concentrations typically ranging from 2% to 10% in topical formulations and has become one of the more studied water-soluble actives in cosmetic chemistry precisely because its targets are structural rather than superficial.

This piece concerns what niacinamide actually changes at the level of the skin barrier — the protein scaffolding, the intercellular lipid matrix, and the water-retention dynamics that govern how the outermost layers of skin behave. The mechanism is not a single reaction but a cluster of related biochemical events that converge on the same tissue.

How Niacinamide Reaches and Alters Barrier Structures

Once niacinamide is absorbed through the stratum corneum, keratinocytes convert it into nicotinamide adenine dinucleotide (NAD+) and its phosphorylated form, NADP+. These coenzymes are not cosmetic intermediates — they are central to cellular energy metabolism and serve as substrates for dozens of enzymatic reactions inside skin cells. The availability of NAD+ is therefore the upstream event that makes niacinamide's barrier effects possible.

One of the most documented downstream effects is an upregulation of ceramide synthesis. Ceramides are the dominant lipid class in the lamellar bodies of keratinocytes — the organelles that discharge lipids into the intercellular spaces of the stratum corneum. When niacinamide increases NAD+ availability, it supports the enzymatic activity of serine palmitoyltransferase, the rate-limiting enzyme in the de novo ceramide synthesis pathway. More ceramide precursors are produced, which ultimately increases the density of the lipid bilayers between corneocytes. This is why ceramide's role in building the lipid barrier is directly relevant to understanding what niacinamide does — the two mechanisms intersect at the same structural target.

Separately, niacinamide influences the expression of filaggrin, a structural protein that aggregates keratin filaments during terminal differentiation of keratinocytes. Filaggrin is also the primary source of the natural moisturizing factor (NMF) — the collection of hygroscopic compounds, including amino acids, pyrrolidone carboxylic acid, and urocanic acid, that draw water into the corneocyte and retain it within the stratum corneum. By supporting filaggrin expression, niacinamide indirectly sustains the NMF pool, which keeps the stratum corneum hydrated and mechanically flexible.

A third mechanism involves the tight junction proteins — claudins, occludins, and zona occludens proteins — that regulate paracellular permeability in the viable epidermis below the stratum corneum. Research suggests niacinamide promotes the expression of these proteins, tightening the second line of defense against transepidermal water loss (TEWL) and external irritants that have already passed through the lipid matrix above.

The Structural Components Niacinamide Engages

Keratinocytes are the primary cellular target. As the dominant cell type in the epidermis, they both metabolize niacinamide into NAD+ and carry out the downstream synthesis of ceramides and filaggrin. The degree of response depends on the differentiation stage of the keratinocyte — cells in the spinous and granular layers are the most metabolically active participants.

Ceramides are the lipid molecules most directly affected by niacinamide-driven synthesis changes. The stratum corneum's lamellar lipid matrix is roughly 50% ceramides by weight, and this proportion is what gives the skin barrier its mechanical resistance to water movement and external chemical penetration. An increase in ceramide production measurably reduces TEWL in controlled studies.

Filaggrin and NMF components form a secondary target. Filaggrin's proteolytic breakdown products — the amino acids and related compounds that make up NMF — are hygroscopic, meaning they bind and retain water molecules within the corneocyte interior. Their concentration directly correlates with stratum corneum hydration levels measured by corneometry.

Tight junction proteins in the stratum granulosum represent a third structural party. These transmembrane proteins form a physical seal between adjacent keratinocytes and contribute to the barrier's permeability selectivity independently of the lipid matrix above them.

NADH-dependent enzymes involved in lipid and protein synthesis are the biochemical intermediaries throughout. Without adequate NAD+, the enzymatic reactions that produce ceramides and support filaggrin expression slow down, which is why the coenzyme conversion step is the true rate-limiting factor in niacinamide's barrier activity.

Where the Niacinamide–Barrier Relationship Breaks Down

The ceramide synthesis pathway that niacinamide supports requires multiple cofactors beyond NAD+ alone — zinc, for example, is a cofactor for several enzymes in the sphingolipid pathway. A formulation that delivers niacinamide in isolation does not address cofactor limitations elsewhere in the pathway, which means the ceramide-upregulating effect is not assured when other nutritional or enzymatic constraints are present.

Niacinamide's interaction with ascorbic acid (vitamin C) in the same formulation has been a persistent subject of debate. The concern is that the two compounds can form a 1:1 charge-transfer complex — nicotinic acid and dehydroascorbic acid — that gives the mixture a yellow tint. Early literature suggested this complex reduced the efficacy of both actives. More recent analysis indicates the reaction is slow at room temperature and at typical cosmetic pH ranges, and that the yellow discoloration is largely aesthetic rather than a sign of full degradation. However, high-temperature storage or prolonged exposure to light can accelerate the reaction, and the extent of efficacy loss in any specific product is not assured without independent stability testing.

Filaggrin expression is genetically variable. Loss-of-function mutations in the FLG gene — present in a significant portion of the population — reduce baseline filaggrin production regardless of niacinamide availability. In individuals with these mutations, the NMF pathway is structurally compromised upstream of any topical intervention, and the magnitude of niacinamide's effect on stratum corneum hydration is likely smaller than in individuals with intact FLG expression.

Concentration also introduces non-linear effects. Studies demonstrating barrier-relevant outcomes have used concentrations between 2% and 5%. At concentrations above approximately 5%, some individuals report transient flushing — a response attributed not to niacinamide itself but to trace amounts of nicotinic acid (niacin) that may be present as a breakdown product or impurity. This response is a vasodilatory reaction in the dermis and is not a barrier mechanism, but it is an expected friction point in higher-concentration formulations.

Finally, niacinamide addresses the lipid and protein components of the barrier but does not directly influence the physical integrity of the corneocyte envelope — the cross-linked protein shell that gives each dead skin cell its structural rigidity. That process is governed by transglutaminase enzymes and their substrates (involucrin, loricrin, cornifin), which operate on a separate regulatory pathway.

What a Niacinamide Label Shows and What It Leaves Out

In the United States, niacinamide is classified as a cosmetic ingredient rather than an over-the-counter drug active when used for barrier and hydration purposes. This means it is not subject to the FDA's OTC drug monograph system that governs actives like sunscreen filters or acne treatments. A label listing "niacinamide" at a stated percentage is providing voluntary disclosure — there is no regulatory requirement to specify the concentration, and many formulations omit it.

The INCI (International Nomenclature of Cosmetic Ingredients) name "niacinamide" is specific and unambiguous. It should not be confused with "niacin" (nicotinic acid) or "inositol hexanicotinate," which are different compounds with different biological activities and different skin-response profiles. A label that reads "niacinamide" is accurately identifying the compound; a label that reads "vitamin B3" without further specification leaves the exact form unclear.

What the label does not show is the formulation's pH. Niacinamide is stable across a relatively wide pH range (approximately 3.5 to 7.4), but the surrounding formula's pH affects how other actives in the same product behave and how quickly any nicotinic acid impurities may accumulate. The label also does not disclose the concentration of those impurities, the presence of cofactor nutrients, or the stability data that would indicate how much active niacinamide remains at the end of the product's shelf life.

Claims on packaging that reference "barrier support," "skin hydration," or "pore appearance" are cosmetic claims and are not evaluated for accuracy by the FDA before a product reaches market. The underlying chemistry described in this piece reflects peer-reviewed research on the ingredient category, not any specific product's tested performance.

Niacinamide's barrier activity is mechanistically grounded in coenzyme biochemistry — it is not a surface-level effect, but the magnitude and consistency of that effect depend on variables that a concentration percentage on a label cannot capture, including individual filaggrin genetics, formulation stability, and the cofactor environment inside the keratinocyte.

Note: This explains how skincare ingredients and products work. It is not a skincare routine, it does not diagnose or treat a skin condition, and it is not a substitute for a dermatologist. Check the cited sources for current guidance.